PLASMA DERIVED MEDICINE MARKET ANALYSIS

Regional Analysis

To learn more about this report, request sample copy

North America has established itself as the dominant region in the global plasma derived medicine market with an estimated market share of 40.3% in 2024. The presence of major industry players such as Shire, CSL Behring and Grifols has boosted the market growth in the region. These leading companies have continued to invest heavily in R&D as well as in expanding their product portfolios. Rising healthcare expenditure and presence of advanced medical facilities have boosted demand for plasma derived drugs. The favorable regulatory environment under FDA also attract new players to set up their manufacturing facilities in the region.

Europe has the most developed plasma collection infrastructure with countries like Germany and Austria at the forefront. The region witnesses millions of plasma collection on a regular basis. This abundant plasma resource has enabled European companies to establish themselves as leading exporters of plasma derived medicines. Key markets like Germany and U.K. dominate the imports for rest of the world. However, increasing presence of U.S players has intensified the competition for European companies in their home markets.

China has emerged as the fastest growing regional market for plasma derived medicine. Rapid economic growth, growing medical needs and rising healthcare expenditures drive the market growth. The government's push for developing domestic biologics industry and reducing imports dependence has attracted significant investments from multinational companies for setting up local plasma fractionation facilities. Regional self-sufficiency holds the potential to make China a global production powerhouse.